This observation indicates that the mode of action of Vandetanib is primarily through tumor associated-endothelial cells and subsequent blood vasculature reduction rather than via direct inhibition of RET in MTC tumor cells, as previously observed in preclinical model of colon cancers [29]. Here, RET is linked to neoplasm.